Introduction {#sec1}
============

Cancer is one of the common health burden worldwide. Due to the prevalence of smoking and drinking, environmental pollution, as well as population aging, the incidence of malignancy is rising. According to the estimation of Global Cancer Statistics 2018, approximately 18.1 million new cancer cases and 9.6 million cancer-related deaths may have occurred in 2018 \[[@B1]\]. In the developing countries, the prognosis of cancer could be poorer than that in the developed countries. The reason of this phenomenon may be due to the diagnosis at an advanced stage combined with limited treatment. Some effective measures can potentially contribute to relieve the global cancer burden, including the application of precise early detection and treatment, tobacco and alcohol control, vaccine injection, sufficient fruits and vegetables intake and appropriate physical exercise. Overweight/obesity influences the health of more than 200 million people \[[@B2]\]. Overweight/obesity may play a vital role in growing morbidity of malignancy \[[@B3],[@B4],[@B5]\]. Thus, it is believed that overweight/obesity-related genes could affect the development of cancer.

Overweight/obesity is attributable to a chronic energy intake and expenditure imbalance. Leptin (LEP) is a common hormone of regulating energy expenditure by inhibiting hunger. LEP receptor (LEPR) is a type I cytokine receptor which is encoded by the *LEPR* gene and acts as a receptor for the hormone LEP. LEPR is a single transmembrane-domain receptor and composed of extracellular, transmembrane, and intracellular sections. LEP/LEPR signaling may involve in promoting angiogenesis, facilitating cell proliferation, and inhibiting epithelial cell apoptosis \[[@B6]\]. The long isoform in LEPR cytoplasmic domain may be essential for the signal transduction of Janus kinase/signal transducers and activators of transcription pathway \[[@B7]\].

The *LEPR* gene lies in chromosome 1 (Position_38: 65420652 -- 65637493). There are a number of common single nucleotide polymorphisms (SNPs) of the *LEPR* genes, which have been established. *LEPR* rs1137101 G\>A polymorphism (Arg223Gln) is the most extensively studied association of this SNP with the development of cancer. *LEPR* rs1137101 locus is a missense variant, which is a substitution of G→A at nucleotide number 668 in exon 6 of *LEPR* gene \[[@B8]\]. It leads to an Arg→Gln altering in extracellular region \[[@B8]\]. The potential relationships of *LEPR* rs1137101 variants with susceptibility of cancer have been elucidated in different malignancies; however, the obtained results were inconsistent. Two previous meta**-**analyses indicated that *LEPR* rs1137101 G\>A polymorphism might not be a risk factor for cancer \[[@B9],[@B10]\]. Recently, more studies concerning the association of *LEPR* rs1137101 locus with cancer risk were performed \[[@B11]\]. Hence, we carried out an updated meta-analysis on such relationship so as to further explore the role of *LEPR* rs1137101 variants to susceptibility of cancer.

Materials and methods {#sec2}
=====================

Searching publications {#sec2-1}
----------------------

To obtain the potentially eligible investigations on *LEPR* rs1137101 G\>A polymorphism and cancer susceptibility, we conducted an electronic literature search on PubMed and Embase databases, covering all publications up to 14 October 2018, by using the following searching strategy: (Leptin receptor or LEPR or obese receptor or OBR or CD295) and (carcinoma or cancer or tumor or malignancy or neoplasms) and (polymorphism or SNP or variation). References of the eligible studies and reviews were also screened to identify the additional data. We reported the present study using the Preferred Reporting Items for PRISMA guideline (Supplementary Table S1; PRISMA checklist) \[[@B27]\].

Selection and exclusion criteria {#sec2-2}
--------------------------------

The major selection criteria were: (i) full-text study, (ii) assessing the relationship of *LEPR* rs1137101 variants with cancer susceptibility, (iii) designed as an unrelated case--control study, (iv) sufficient data could be obtained to calculate the odds ratio (OR) with 95% confidence interval (CI), and (v) genotype distribution conformation to Hardy--Weinberg equilibrium (HWE).

The major exclusion criteria were: (i) genotype data could not be extracted; (ii) not case--control study; (iii) distribution of genotype violated HWE; and (iv) comments, reviews, and letters.

Data extraction {#sec2-3}
---------------

Two authors (G.R. and Y.W.) independently extracted raw data. The following data were collected: the surname of first author, publication year, race, country, number of participants, age, Body Mass Index (BMI), source of control, matching method, genotype frequencies and genotyping method. Ethnicity descents were defined as mixed, Asian, and Caucasian. Cancer types were classified as hepatocellular carcinoma, breast cancer, renal cell carcinoma, esophageal cancer, colorectal cancer, oral and oropharyngeal cancer, non-Hodgkin's lymphoma and other cancers (lung cancer and bladder cancer). For source of control, the eligible studies were categorized as hospital-based and population-based. When HWE in control group was not available, an online software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was harnessed to calculate the *P-*value of HWE test. If the information extracted was different, two authors reached consensus on each item.

Statistical analysis {#sec2-4}
--------------------

The relationship strength of *LEPR* rs1137101 SNP with susceptibility of cancer was determined by crude ORs with their 95% CIs. The pooled ORs were calculated for allele (A vs. G), dominant (GA/AA vs. GG), recessive (AA versus GA/GG), and homozygote comparison (AA vs. GG) genetic modes. Additionally, stratified analysis was carried out to assess the influence of confounding risk factors: ethnicity (mixed, Asian, and Caucasian) and cancer type (breast cancer, esophageal cancer, hepatocellular carcinoma, renal cell carcinoma, colorectal cancer, oral and oropharyngeal cancer, non-Hodgkin's lymphoma, and other cancers). We used Chi-square based Q-test and *I^2^* test to assess the potential heterogeneity among the eligible studies. *P*\<0.10 or *I^2^* ≥ 50% was considered as the level of significant heterogeneity. Then a random-effects model (DerSimonian and Laird method) was used to assess the association of *LEPR* rs1137101 polymorphism with cancer susceptibility \[[@B28],[@B29]\]; otherwise, a fixed-effects model (Mantel--Haenszel method) was harnessed to pool the data \[[@B30]\]. Stratified analysis was conducted to explore the source of heterogeneity. We performed one-way sensitivity analysis to evaluate the effect of an individual study on pooled ORs and CIs. Begg's funnel plot and the Egger's test were used to detect the potential bias in included publications, and a *P*\<0.10 was considered significant \[[@B31],[@B32]\]. Statistical analysis of the present study was calculated with STATA 12.0 software (StataCorp, College Station, Texas, U.S.A.).

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

In this meta-analysis, 33 publications involving 44 independent case--control studies on the relationship of *LEPR* rs1137101 G\>A polymorphism with cancer risk were recruited \[[@B9],[@B11],[@B33]\]. In some publications, they contained several subgroups that we treated as independent studies \[[@B12],[@B14],[@B40]\]. [Figure 1](#F1){ref-type="fig"} shows the eligible study selecting process. In total, 44 independent case--control studies with 35,936 subjects (13,711 cases and 22,225 controls) were included. Among them, 20 were Caucasians \[[@B15],[@B16],[@B20],[@B34],[@B36],[@B37],[@B39],[@B45]\], 14 were Asians \[[@B9],[@B11],[@B17],[@B24],[@B26],[@B33],[@B44]\], 1 was African \[[@B38]\], and 9 were mixed populations \[[@B18],[@B19],[@B25],[@B35]\]. Twenty-two case--control studies were designed as hospital-based investigation \[[@B9],[@B11],[@B17],[@B18],[@B21],[@B22],[@B24],[@B26],[@B33],[@B34],[@B38],[@B44],[@B46],[@B48]\], seventeen studies were designed as population-based investigation \[[@B16],[@B19],[@B25],[@B35],[@B40],[@B41],[@B43],[@B45],[@B47]\], and the source of control in other five studies were unknown \[[@B15],[@B20],[@B23],[@B39],[@B42]\]. Of all the eligible studies, 24 focused on breast cancer \[[@B12],[@B14],[@B15],[@B19],[@B20],[@B22],[@B33],[@B35],[@B36],[@B38],[@B41],[@B42],[@B44],[@B47],[@B48]\], 4 focused on esophageal cancer \[[@B13],[@B40]\], 4 focused on colorectal cancer \[[@B34],[@B37],[@B39],[@B46]\], 3 focused on hepatocellular carcinoma \[[@B9],[@B11],[@B26]\], 2 focused on non-Hodgkin's lymphoma \[[@B43],[@B45]\], 3 focused on oral and oropharyngeal cancer \[[@B18],[@B21],[@B25]\], 2 focused on renal cell carcinoma \[[@B17],[@B24]\], and 2 focused on other cancers \[[@B16],[@B23]\]. The detailed information of eligible studies is listed in [Table 1](#T1){ref-type="table"}. The extracted genotypes and HWE are summarized in [Table 2](#T2){ref-type="table"}. Figure 1Flow diagram of the meta--analysis of the association between *LEPR* rs1137101 G\>A polymorphism and cancer risk

###### Characteristics of the studies in meta-analysis

  Study                  Publication year   Country          Ethnicity    Cancer type                     Sample size (case/control)   Case age (years)      Control age (years)   Case BMI (kg/m^2^)                            Control BMI (kg/m^2^)                         Source of control   Match                                          Genotype method
  ---------------------- ------------------ ---------------- ------------ ------------------------------- ---------------------------- --------------------- --------------------- --------------------------------------------- --------------------------------------------- ------------------- ---------------------------------------------- --------------------------------
  Zhang et al.           2018               China            Asians       Hepatocellular carcinoma        584/923                      53.17 ± 11.76         53.72 ± 9.97          NA                                            NA                                            Hospital-based      Age, sex, ethnicity                            SNPscan
  Liu et al.             2018               China            Asians       Breast cancer                   488/463                      43.71 ± 6.13          43.35 ± 5.43          BMI \< 24: *n*=300, BMI ≥ 24, *n*=148         BMI \< 24: *n*=289, BMI ≥ 24, *n*=174         Hospital-based      Age, sex, ethnicity, region                    MS-TOF
  Liu et al.             2018               China            Asians       Breast cancer                   346/342                      58.55 ± 6.87          56.60 ± 6.53          BMI \< 24:*n*=207, BMI ≥ 24, *n*=139          BMI \< 24: *n*=195, BMI ≥ 24, *n*=147         Hospital-based      Sex, ethnicity, region                         MS-TOF
  Qiu et al.             2017               China            Asians       Esophageal cancer               507/1,496                    62.77 ± 8.01          62.77 ± 8.84          22.27 ± 2.90                                  23.91 ± 3.03                                  Hospital-based      Age, ethnicity, sex                            SNPscan
  Yuna et al.            2018               China            Asians       Breast cancer                   77/805                       51.43 ± 11.33         48.98 ± 8.83          Obesity (≥27): *n*=15, non-obesity, *n*=62    Obesity (≥27), *n*=50, non-obesity, *n*=751   Hospital-based      Age, sex, ethnicity, region                    MS-TOF
  Yuna et al.            2019               China            Asians       Breast cancer                   79/805                       49.94 ± 10.10         48.98 ± 8.83          Obesity (≥27), *n*=12, non-obesity, *n*=67    Obesity (≥27), *n*=50, non-obesity, *n*=751   Hospital-based      Age, sex, ethnicity, region                    MS-TOF
  Yuna et al.            2017               China            Asians       Breast cancer                   412/805                      49.73 ± 9.38          48.98 ± 8.83          Obesity (≥27), *n*=45, non-obesity, *n*=365   Obesity (≥27), *n*=50, non-obesity, *n*=751   Hospital-based      Age, sex, ethnicity, region                    MS-TOF
  Yuna et al.            2017               China            Asians       Breast cancer                   135/805                      50.50 ± 9.04          48.98 ± 8.83          Obesity (≥27), *n*=12, non-obesity, *n*=123   Obesity (≥27), *n*=50, non-obesity, *n*=751   Hospital-based      Age, sex, ethnicity, region                    MS-TOF
  El-Hussiny et al.      2017               Egypt            Caucasians   Breast cancer                   48/48                        47.7 ± 7.5            43.5 ± 9.2            34.37 ± 6.08                                  27.28 ± 3.52                                  NA                  Sex, ethnicity, region                         PCR-RFLP
  Ali et al.             2017               Pakistan         Caucasians   Bladder cancer                  200/200                      55.5 ± 13.24          54.3 ± 9.9            NA                                            NA                                            Population-based    Age, sex, ethnicity                            PCR
  Zhang et al.           2016               China            Asians       Renal cell carcinoma            83/161                       17--85 (median: 57)   NA                    NA                                            NA                                            Hospital-based      Ethnicity, age, and sex                        PCR-RLFP
  Rodrigues et al.       2015               Brazil           Mixed        Oral and oropharyngeal cancer   129/186                      54.9 ± 10.7           54.2 ± 11.1           NA                                            NA                                            Hospital-based      Sex, region                                    PCR-RLFP
  Slattery et al.        2015               America          Mixed        Breast cancer                   239/252                      NA                    NA                    BMI \< 25                                     BMI \< 25                                     Population-based    Sex, region                                    A multiplexed bead array assay
  Slattery et al.        2015               America          Mixed        Breast cancer                   176/150                      NA                    NA                    BMI = 25--29                                  BMI = 25--29                                  Population-based    Sex, region                                    A multiplexed bead array assay
  Slattery et al.        2015               America          Mixed        Breast cancer                   111/126                      NA                    NA                    BMI **≥ 30**                                  BMI **≥ 30**                                  Population-based    Sex, region                                    A multiplexed bead array assay
  Slattery et al.        2015               America          Mixed        Breast cancer                   253/239                      NA                    NA                    BMI \< 25                                     BMI \< 25                                     Population-based    Sex, region                                    A multiplexed bead array assay
  Slattery et al.        2015               America          Mixed        Breast cancer                   205/304                      NA                    NA                    BMI = 25--29                                  BMI = 25--29                                  Population-based    Sex, region                                    A multiplexed bead array assay
  Slattery et al.        2015               America          Mixed        Breast cancer                   148/224                      NA                    NA                    BMI ≥ 30                                      BMI ≥ 30                                      Population-based    Sex, region                                    A multiplexed bead array assay
  Mahmoudi et al.        2015               Iran             Caucasians   Breast cancer                   45/41                        47.09 ± 11.45         48.37 ± 8.80          NA                                            NA                                            NA                  Age, sex                                       PCR-RFLP
  Hussain et al.         2015               India            Caucasians   Oral carcinoma                  306/228                      33.5 ± 5.79           32.7 ± 5.73           29.5 ± 5.44                                   23.8 ± 4.88                                   Hospital-based      Age, sex, ethnicity and low-risk environment   PCR-RFLP
  Mohammadzadeh et al.   2014               Iran             Caucasians   Breast cancer                   100/100                      48.16 ± 10.47         49.0 ± 7.77           27.16 ± 3.96                                  28.31 ± 4.71                                  Hospital-based      Age, sex, ethnicity, BMI                       PCR-RFLP
  Unsal et al.           2014               Turkey           Caucasians   Lung cancer                     162/130                      60.96 ± 11.88         57.92 ± 14.96         NA                                            NA                                            NA                  Age, sex, ethnicity                            PCR-RFLP
  Mu et al.              2014               China            Asians       Renal cell carcinoma            77/161                       56.22 ± 12.27         NA                    NA                                            NA                                            Hospital-based      Ethnicity, age and sex                         PCR-RFLP or DNA sequence
  Domingos et al.        2014               Brazil           Mixed        Oral carcinoma                  25/89                        58.0 ± 13.6           55.9 ± 13.9           NA                                            NA                                            Population-based    Age, sex, and smoking habits                   RFLP-PCR
  Li et al.              2012               China            Asians       Hepatocellular carcinoma        417/551                      52.45 ± 4.6           51.95 ± 2.8           21.44 ± 3.4                                   22.56 ± 3.2                                   Hospital-based      Age, sex, ethnicity                            RFLP
  Kim et al.             2012               Korea            Asians       Breast cancer                   400/452                      ≤49: 64.8%            ≤49: 62.4%            ≤25: 68.5%                                    ≤25: 78.5%                                    Hospital-based      Age, sex                                       MS-TOF
  Karimi et al.          2011               Iran             Caucasians   Colorectal cancer               173/173                      55.8 ± 12.7           44.8 ± 17.2           25.1 ± 5.3                                    26.2 ± 7.19                                   Hospital-based      BMI, sex and smoking status                    RFLP
  Nyante et al.          2011               America          Mixed        Breast cancer                   1972/1776                    23--74, mean: 50      21--74, mean: 51      BMI \< 25, *n*=712; BMI ≥ 25, *n*=1219        BMI \< 25, *n*=545; BMI ≥ 25, *n*=1194        Population-based    Age, sex and region                            Illumina
  Cleveland et al.       2010               America          Caucasians   Breast cancer                   1065/1108                    NA                    NA                    BMI \< 30, *n*=291; BMI ≥ 30, *n*=43          BMI \< 30, *n*=304; BMI ≥ 30, *n*=62          Population-based    Age, sex, region                               PCR
  Pechlivanis et al.     2009               Czech Republic   Caucasians   Colorectal cancer               702/752                      27--85, mean: 62      29--91, mean: 54      13.1--44.9, mean: 26.5                        16.6--44.3, mean: 26.4                        Hospital-based      Sex, region                                    TaqMan
  Okobia et al.          2008               Nigeria          Africans     Breast cancer                   209/209                      46.1 ± 12.63          47.1 ± 13.50          NA                                            NA                                            Hospital-based      Sex, region                                    PCR-RFLP
  Vasků et al.           2009               Czech Republic   Caucasians   Colorectal cancer               102/101                      68 ± 10.2             68.1 ± 5.4            Male/Female: 26.7 ± 5.1/26.9 ± 5.2            NA                                            NA                  Age, ethnicity                                 PCR-RFLP
  Doecke et al.          2008               Australia        Caucasians   Esophageal cancer               260/1352                     NA                    NA                    NA                                            NA                                            Population-based    Sex, region                                    Sequenom
  Doecke et al.          2008               Australia        Caucasians   Esophageal cancer               301/1352                     NA                    NA                    NA                                            NA                                            Population-based    Sex, region                                    Sequenom
  Doecke et al.          2008               Australian       Caucasians   Esophageal cancer               213/1352                     NA                    NA                    NA                                            NA                                            Population-based    Sex, region                                    Sequenom
  Gallicchio et al.      2007               America          Caucasians   Breast cancer                   61/933                       mean: 59              mean: 59              NA                                            BMI \< 25, *n*=479; BMI ≥ 25, *n*=513         Population-based    NA                                             TaqMan
  Snoussi et al.         2006               Tunisia          Caucasians   Breast cancer                   308/222                      50 ± 24               48 ± 14               NA                                            NA                                            NA                  Sex, region                                    PCR-RFLP
  Willett et al.         2005               U.K.             Caucasians   Non-Hodgkin's lymphoma          1073/754                     18--65                18--65                BMI \< 25, *n*=633, BMI ≥ 25, *n*=603         BMI \< 25, *n*=524; BMI ≥ 25, *n*=387         Population-based    Sex, region                                    TaqMan
  Woo et al.             2006               Korea            Asians       Breast cancer                   45/45                        NA                    NA                    BMI \< 25, *n*=27, BMI ≥ 25, *n*=18           BMI \< 25, *n*=37; BMI ≥ 25, *n*=8            Hospital-based      Age, sex                                       DNA sequencing
  Skibola et al.         2004               America          Caucasians   Non-Hodgkin's lymphoma          376/805                      21--74                NA                    BMI \< 25, *n*=213; BMI ≥ 25, *n*=162         BMI \< 25: *n*=480; BMI ≥ 25, *n*=321         Population-based    Age, sex and region                            TaqMan
  Mahmoudi et al.        2016               Iran             Caucasians   Colorectal cancer               261/339                      56.1 ± 12.6           44.3 ± 16.3           25.6 ± 4.9                                    25.2 ± 4.2                                    Hospital-based      Sex and BMI                                    PCR-RFLP
  Dai et al.             2010               China            Asians       Hepatocellular carcinoma        80/102                       32--65                28--60                NA                                            NA                                            Hospital-based      Age, sex, ethnicity                            PCR-RFLP
  Teras et al.           2009               America          Caucasians   Breast cancer                   648/659                      mean: 69              mean: 69              NA                                            NA                                            Population-based    Age, sex                                       SNPstream
  Kuptsova et al.        2008               Russia           Caucasians   Breast cancer                   110/105                      56--65                50--70                NA                                            NA                                            Hospital-based      Age, sex                                       PCR

Abbreviations: MS-TOF, mass spectrometry time of flight; NA, not available; PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism.

###### Distribution of *LEPR* rs1137101 G\>A polymorphism genotype and allele

  Study                  Publication year   Case          Control   Case        Control       HWE                                                                            
  ---------------------- ------------------ ------------- --------- ----------- ------------- ----- ----------- -------------- -------------- -------------- --------------- -----
  Zhang et al.           2018               3             119       453         10            193   717         125 (10.87)    1025 (89.13)   213 (11.58)    1627 (88.42)    Yes
  Liu et al.             2018               AA/AG = 101   NA        346         AA/AG = 99    NA    363         NA             NA             NA             NA              Yes
  Liu et al.             2018               AA/AG = 80    NA        264         AA/AG = 79    NA    260         NA             NA             NA             NA              Yes
  Qiu et al.             2017               6             108       390         21            322   1146        120 (11.90)    888 (88.10)    364 (12.22)    2,614 (87.78)   Yes
  Yuan et al.            2017               AA/AG = 18    NA        59          AA/AG = 178   NA    623         NA             NA             NA             NA              Yes
  Yuan et al.            2017               AA/AG = 17    NA        62          AA/AG = 178   NA    623         NA             NA             NA             NA              Yes
  Yuan et al.            2017               AA/AG = 96    NA        314         AA/AG = 178   NA    623         NA             NA             NA             NA              Yes
  Yuan et al.            2017               AA/AG = 30    NA        105         AA/AG = 178   NA    623         NA             NA             NA             NA              Yes
  El-Hussiny et al.      2017               9             15        24          2             24    22          33 (34.38)     63, 65.63)     28 (29.17)     68 (70.83)      Yes
  Ali et al.             2017               51            96        53          67            97    36          198 (49.50)    202 (50.50)    231 (57.75)    169 (42.25)     Yes
  Zhang et al.           2016               2             21        61          7             52    102         25 (14.88)     143 (85.12)    66 (20.50)     256 (79.50)     Yes
  Rodrigues et al.       2015               60            61        8           68            92    26          181 (70.16)    77 (29.84)     228 (61.29)    144 (38.71)     Yes
  Slattery et al.        2015               77            NA        AG/GG:162   69            NA    AG/GG:183   NA             NA             NA             NA              Yes
  Slattery et al.        2015               50            NA        AG/GG:126   50            NA    AG/GG:100   NA             NA             NA             NA              Yes
  Slattery et al.        2015               22            NA        AG/GG:89    38            NA    AG/GG:88    NA             NA             NA             NA              Yes
  Slattery et al.        2015               63            NA        AG/GG:190   80            NA    AG/GG:159   NA             NA             NA             NA              Yes
  Slattery et al.        2015               46            NA        AG/GG:159   83            NA    AG/GG:221   NA             NA             NA             NA              Yes
  Slattery et al.        2015               43            NA        AG/GG:105   52            NA    AG/GG:172   NA             NA             NA             NA              Yes
  Mahmoudi et al.        2015               19            25        1           17            18    6           63 (70.00)     27 (30.00)     52 (63.41)     30 (36.59)      Yes
  Hussain et al.         2015               48            110       148         12            72    144         206 (33.66)    406 (66.34)    96 (21.05)     360 (78.95)     Yes
  Mohammadzadeh et al.   2014               25            56        19          54            40    6           106 (53.000)   94 (47.00)     148 (74.00)    52 (26.00)      Yes
  Unsal et al.           2014               75            62        25          56            55    19          212 (65.43)    112 (34.57)    167 (64.23)    93 (35.77)      Yes
  Mu et al.              2014               2             20        55          4             41    116         24 (15.58)     130 (84.42)    49 (15.22)     273 (84.78)     Yes
  Domingos et al.        2014               12            7         6           40            38    11          31 (62.00)     19 (38.00)     118 (66.29)    60 (33.71)      Yes
  Li et al.              2012               87            208       122         189           256   106         382 (45.80)    452 (54.20)    634 (57.53)    468 (42.47)     Yes
  Kim et al.             2012               8             88        294         6             91    350         104 (13.33)    676 (86.67)    103 (11.52)    791 (88.48)     Yes
  Karimi et al.          2011               77            75        21          67            80    26          229 (66.18)    117 (33.82)    214 (61.85)    132 (38.15)     Yes
  Nyante et al.          2011               494           952       526         416           874   485         1940 (49.19)   2004 (50.86)   1706 (48.06)   1844 (51.94)    Yes
  Cleveland et al.       2010               173           521       355         187           551   360         867 (41.33)    1231 (58.67)   925 (42.12)    1271 (57.88)    Yes
  Pechlivanis et al.     2009               179           320       140         202           361   143         678 (53.05)    600 (46.95)    765 (54.18)    647 (45.82)     Yes
  Okobia et al.          2008               46            107       56          56            107   46          199 (47.61)    219 (52.39)    219 (52.39)    199 (47.61)     Yes
  Vasků et al.           2009               23            56        21          34            45    21          102 (51.00)    98 (49.00)     113 (56.50)    87 (43.50)      Yes
  Doecke et al.          2008               73            140       47          419           663   270         286 (55.00)    234 (45.00)    1501 (55.51)   1203 (44.49)    Yes
  Doecke et al.          2008               84            164       62          419           663   270         332 (53.55)    288 (46.45)    1501 (55.51)   1203 (44.49)    Yes
  Doecke et al.          2008               64            106       43          419           663   270         234 (54.93)    192 (45.07)    1501 (55.51)   1203 (44.49)    Yes
  Gallicchio et al.      2007               14            24        15          278           443   151         52 (49.07)     54 (50.94)     999 (57.28)    745 (42.72)     Yes
  Snoussi et al.         2006               98            145       65          102           90    30          341 (55.36)    275 (44.64)    294 (66.22)    150 (33.78)     Yes
  Willett et al.         2005               336           554       183         234           387   133         1226 (57.13)   920 (42.87)    855 (56.70)    653 (43.30)     Yes
  Woo et al.             2006               0             12        33          0             8     37          12 (13.33)     78 (86.67)     8 (8.89)       82 (91.11)      Yes
  Skibola et al.         2004               115           173       87          226           379   198         403 (53.73)    347 (46.27)    831 (51.74)    775 (48.26)     Yes
  Mahmoudi et al.        2016               127           101       33          146           147   46          355 (68.01)    167 (31.99)    439 (64.75)    239 (35.25)     Yes
  Dai et al.             2010               10            14        58          2             19    81          34 (20.73)     130 (79.27)    23 (11.27)     181 (88.73)     Yes
  Teras et al.           2009               AA/AG = 460   NA        181         AA/AG = 439   NA    211         NA             NA             NA             NA              Yes
  Kuptsova et al.        2008               17            69        24          18            51    36          103 (46.82)    117 (53.18)    87 (41.43)     123 (58.57)     Yes

Abbreviation: NA, not available.

Results of meta-analysis {#sec3-2}
------------------------

[Table 3](#T3){ref-type="table"} lists the overall and subgroup analysis results of the present study. After combining all eligible case--control studies, we identified null relationship between rs1137101 polymorphism in *LEPR* gene and overall cancer risk under four genetic models (A *vs.* G: OR  =  0.97, 95% CI  =  0.89--1.06, *P*=0.547; AA *vs.* GG: OR  =  0.93, 95% CI  =  0.78--1.13, *P* =0.476; AA/GA *vs.* GG: OR  =  0.99, 95% CI  =  0.91--1.09, *P*=0.890 and AA *vs.* GA/GG: OR  = 0.92, 95% CI  =  0.82--1.04, *P*=0.198, [Figures 2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}).

![Meta-analysis of the association between *LEPR* rs1137101 G\>A polymorphism and cancer risk (AA/GA vs. GG, random--effects model)](bsr-39-bsr20182240-g2){#F2}
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###### Results of the meta-analysis from different genetic models

                                  Number of studies   A vs. G                 AA vs. GG   AA+GA vs. GG   AA vs.GA+GG                                                                                                                                           
  ------------------------------- ------------------- ----------------------- ----------- -------------- ------------- ------------------- ------- ------- --------- ------------------- ------- ------- --------- ----------------------- ----------- ------- ---------
  Total                           44                  0.97 (0.89--1.06)       0.547       73.4%          \<0.001       0.93 (0.78--1.13)   0.476   70.7%   \<0.001   0.99 (0.91--1.09)   0.890   48.7%   \<0.001   0.92 (0.82--1.04)       0.198       66.2%   \<0.001
  **Ethnicity**                                                                                                                                                                                                                                                
  Caucasians                      20                  0.97 (0.87--1.08)       0.565       73.6%          \<0.001       0.95 (0.77--1.17)   0.621   68.6%   \<0.001   1.00 (0.87--1.15)   0.976   56.9%   0.001     0.93 (0.80--1.09)       0.381       68.4%   \<0.001
  Asians                          14                  0.98 (0.77--1.25)       0.864       76.6           \<0.001       0.88 (0.44--1.79)   0.733   67.7%   0.005     0.96 (0.87--1.06)   0.456   32.2%   0.118     0.91 (0.49--1.69)       0.765       60.1%   0.020
  Mixed                           9                   1.13 (0.87--1.47)       0.369       54.6%          0.110         1.25 (0.61--2.58)   0.539   60.6%   0.050     1.11 (0.55--2.24)   0.775   68.6%   0.041     0.98 (0.80--1.20)       0.837       53.9%   0.027
  Africans                        1                   0.83 (0.63--1.08)       0.167       \-             \-            0.67 (0.39--1.17)   0.162   \-      \-        0.77 (0.49--1.21)   0.255   \-      \-        0.77 (0.49--1.21)       0.255       \-      \-
  **Cancer type**                                                                                                                                                                                                                                              
  Breast cancer                   24                  0.91 (0.77--1.07)       0.248       75.5%          \<0.001       0.82 (0.57--1.17)   0.269   74.6%   \<0.001   1.00 (0.88--1.13)   0.946   44.1%   0.024     0.84 (0.69--1.02)       0.076       67.3%   \<0.001
  Colorectal cancer               4                   1.01 (0.90--1.14)       0.814       30.4%          0.230         1.00 (0.79--1.26)   0.967   0.0%    0.398     0.98 (0.80--1.21)   0.860   0.0%    0.742     1.04 (0.88--1.23)       0.623       48.2%   0.122
  Esophageal cancer               4                   0.96 (0.87--1.06)       0.407       0.0%           0.967         0.93 (0.75--1.16)   0.525   0.0%    0.957     1.01 (0.87--1.18)   0.873   0.0%    0.916     0.88 (0.74--1.03)       0.118       0.0%    0.925
  Hepatocellular carcinoma        3                   0.98 (0.60--1.62)       0.948       89.4%          \<0.001       0.96 (0.21--4.42)   0.956   84.1%   0.002     0.89 (0.55--1.44)   0.633   80.8%   0.005     1.03 (0.25--4.14)       0.971       81.5%   0.005
  Oral and oropharyngeal cancer   3                   **1.46 (1.00--2.13)**   **0.050**   64.1%          0.062         2.02 (0.72--5.65)   0.179   75.1%   0.018     1.43 (0.67--3.07)   0.360   69.1%   0.039     **1.83 (1.01--3.33)**   **0.048**   60.6%   0.079
  Renal cell carcinoma            2                   0.82 (0.57--1.18)       0.291       19.7%          0.264         0.67 (0.21--2.14)   0.500   0.0%    0.509     0.81 (0.53--1.23)   0.318   13.9%   0.281     0.72 (0.22--2.28)       0.570       0.0%    0.576
  Non-Hodgkin's lymphoma          2                   1.04 (0.94--1.16)       0.451       0.0%           0.577         1.09 (0.88--1.35)   0.438   0.0%    0.641     1.06 (0.88--1.28)   0.547   0.0%    0.839     1.05 (0.90--1.24)       0.528       0.0%    0.526
  Others                          2                   0.86 (0.59--1.25)       0.426       65.9%          0.087         0.68 (0.44--1.04)   0.076   55.3%   0.135     0.71 (0.48--1.04)   0.079   9.8%    0.292     0.86 (0.63--1.18)       0.600       60.7%   0.111
  **Sample size**                                                                                                                                                                                                                                              
  \<1000                          32                  0.98 (0.82--1.17)       0.816       81.1%          \<0.001       0.98 (0.67--1.43)   0.913   78.6%   \<0.001   0.97 (0.81--1.15)   0.694   62.4%   \<0.001   0.93 (0.75--1.14)       0.466       72.9%   \<0.001
  ≥1000                           12                  1.00 (0.95--1.05)       0.950       0.0%           0.926         1.01 (0.91--1.11)   0.906   0.0%    0.882     1.02 (0.95--1.09)   0.548   0.0%    0.945     1.00 (0.92--1.08)       0.907       0.0%    0.695
  **Source of control**                                                                                                                                                                                                                                        
  Hospital-based                  22                  1.03 (0.86--1.23)       0.744       82.7%          \<0.001       1.04 (0.68--1.57)   0.869   80.2%   \<0.001   1.03 (0.90--1.19)   0.651   57.4%   \<0.001   0.99 (0.72--1.36)       0.965       78.6%   \<0.001
  Population-based                17                  0.99 (0.94--1.04)       0.715       20.9%          0.251         0.99 (0.87--1.03)   0.787   25.0%   0.214     1.01 (0.94--1.10)   0.754   29.3%   0.167     0.97 (0.90--1.04)       0.368       29.1%   0.132
  NA                              5                   0.92 (0.68--1.23)       0.560       61.7%          0.034         1.02 (0.48--2.13)   0.968   68.6%   0.013     0.82 (0.61--1.10)   0.190   38.7%   0.163     0.89 (0.53--1.48)       0.649       69.4%   0.011

*I^2^*: ≥50% indicate significant heterogeneity. *P* (Q-test): \<0.10 considered as the criterion of significant heterogeneity.

Abbreviation: NA, not available. Bold values are statistically significant (*P*\<0.05).

When we conducted a stratified analysis by ethnicity, null association was found in mixed populations, Africans, Asians, and Caucasians. However, when we performed a subgroup analysis by cancer type, there was an increased susceptibility of oral and oropharyngeal cancer in AA *vs.* GA/GG genetic model (OR, 1.83; 95% CI, 1.01--3.33; *P*=0.048).

Heterogeneity analysis {#sec3-3}
----------------------

Significant heterogeneity among the eligible studies was found in this pooled analysis ([Table 3](#T3){ref-type="table"}). In the present study, we carried out subgroup analysis to explore the sources of heterogeneity. We found that Caucasians, breast cancer, hepatocellular carcinoma, other cancers, small sample sizes (\<1000) and hospital-based case--control studies might contribute the major source to heterogeneity.

Sensitivity analysis {#sec3-4}
--------------------

Sensitivity analysis of one-way method identified that any individual study deleted did not materially influence the pooled ORs and CIs under all genetic comparisons. These findings indicated that our observations were stable and reliable (Supplementary Figure S1).

Publication bias {#sec3-5}
----------------

Begg's funnel plot and Egger's test were used to evaluate the potential bias. The results of the bias detecting were shown as following: A *vs.* G: *P* ~Begg's~= 0.852, *P*~Egger's~ = 0.973; AA *vs.* GG: *P* ~Begg's~= 0.775, *P*~Egger's~ = 0.897; AA/GA *vs.* GG: *P* ~Begg's~ = 0.950, *P*~Egger's~ = 0.869 and AA *vs.* GA/GG: *P* ~Begg's~= 0.703, *P*~Egger's~ = 0.897 (Supplementary Figure S2).

Discussion {#sec4}
==========

Recently, variants in LEPR gene and their potential associations with cancer risk have been explored. Rs1137101 G\>A polymorphism is one of the important variants in *LEPR* gene. *LEPR* rs1137101 G\>A polymorphism is located on the exon region of LEPR gene, and it has been thought to be involved in the development of cancer by a number of studies. Several case--control studies reported that *LEPR* rs1137101 G\>A polymorphism might be associated with the decreased risk of cancer \[[@B16],[@B22],[@B26],[@B41],[@B42]\]. However, several primary studies also suggested that *LEPR* rs1137101 locus could promote the progression of cancers \[[@B15],[@B18]\]. Meanwhile, two meta-analyses were carried out to clarify the correlation of this SNP with susceptibility of overall cancer \[[@B9],[@B10]\]. The results of these meta-analyses indicated that *LEPR* rs1137101 G\>A polymorphism might not be associated with the risk of cancer. Moreover, more epidemiologic data were reported \[[@B11]\]. Therefore, an updated meta-analysis is necessary to calrify this issue precisely. In this meta-analysis, data of 44 case--control studies involving 13,711 cases and 22,225 controls, which is higher compared with these previous pooled-analyses mentioned above, were included and analyzed. Therefore, the obtained results may be more convincing.

LEP/LEPR signaling may promote cell proliferation and inhibit epithelial cell apoptosis \[[@B6]\]. In addition, Ben et al. \[[@B49]\] reported that *LEPR* rs1137101 G\>A SNP may affect plasma LEP levels and BMI. A previous study suggested that leptin level was associated with the development of breast cancer \[[@B50]\]. However, null associations of *LEPR* rs1137101 locus with cancer susceptibility was identified, which was analogous to the results reported in previous meta-analyses \[[@B9],[@B10],[@B51],[@B52]\], but unlike the other four meta-analyses \[[@B48],[@B53]\]. Due to lack of sufficient data, the findings of previous systematic reviews and meta-analyses might be conflicting. Ethnicity also may be a vital factor for the difference. The minor allele frequency of *LEPR* rs1137101 G\>A polymorphism was difference among different populations, but in stratified analysis by race, null relationship was found. Additionally, results of stratified analyses by sample size and source of control both found no relationship between *LEPR* rs1137101 G\>A polymorphism with overall cancer susceptibility, highlighting that these variables could not influence the negative findings either.

According to the findings of stratified analysis, we found that *LEPR* rs1137101 locus might be associated with the susceptibility of oral and oropharyngeal cancer. However, the increased risk of cancer was dubious and hard to explain. Sample size was an important factor to determine the relationship between *LEPR* rs1137101 G\>A polymorphism and cancer risk. In this subgroup, only 460 oral and oropharyngeal cancer cases and 503 controls were included for analysis, the findings might be underpowered.

Significant heterogeneity was found among the eligible studies in multiple genetic models. Thus, we carried out stratified analysis by ethnicity, cancer type, sample size, and source of control. It was obvious that Caucasians, hepatocellular carcinoma, breast cancer, other cancers, small sample sizes (\<1000 subjects) and hospital-based case--control studies might contribute to heterogeneity.

In this meta-analysis, as mentioned in results, no publication bias was detected. In addition, findings of sensitivity analysis also indicated that our observation was convincing. Overall, results of this meta-analysis were stable and credible for the studied populations.

However, there were several limitations in the present pooled-analysis. First, some small sample size studies were recruited in this meta-analysis, which could promote the power of study. On the other hand, they led to potential publication bias and significant heterogeneity as well. Second, our findings were based on the crude pooled-results of the eligible case--control studies, the adjustment on characteristics and risk factors (e.g. BMI, physical exercise, age, gender, smoking, alcohol consumption, vegetable and fruit intake, and so on) was not performed. In the future, a more detailed assessment is needed, in which the characteristics and potential risk factors should be considered to adjust the findings. Third, although the cases and controls in eligible studies were fully matched, there was heterogeneity in different cancer types which may influence our results. Fourth, only PubMed and Embase databases were searched to retrieve the eligible. Finally, significant heterogeneity was found in all genetic models, which might influence the findings of our study. Thus, these results should be interpreted with caution.

In summary, this meta-analysis may be the largest sample size so far to assess the potential association of cancer risk with rs1137101 G\>A polymorphism in *LEPR* gene. There is no significant association of cancer risk was identified to be correlated with rs1137101 G\>A variants in the overall comparison, and the similar findings was also found in stratified analysis by ethnicity, cancer type, sample size, and source of control. In the future, more large-scale studies are needed to confirm or refute our findings.
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